Crossmark

Adjuvant immune checkpoint inhibitors associated with higher recurrence-free survival in postoperative hepatocellular carcinoma (PREVENT): a prospective, multicentric cohort study

Crossref DOI link: https://doi.org/10.1007/s00535-023-02018-2

Published Online: 2023-07-14

Published Print: 2023-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Li, Le

Wu, Pei-Sheng

Liang, Xiu-Mei

Chen, Kang

Zhang, Guan-Lan

Su, Qi-Bin

Huo, Rong-Rui

Xie, Rong-Wei

Huang, Shan

Ma, Liang

Zhong, Jian-Hong https://orcid.org/0000-0002-1494-6396
Funding

Funding for this research was provided by:

Specific Research Project of Guangxi for Research Bases and Talents (GuiKe AD22035057)

National Natural Science Foundation of China (82060510)

National Natural Science Foundation of China (82260569)

Key Laboratory of Early Prevention and Treatment for Regional High Frequency Tumor (Guangxi Medical University), Ministry of Education (GKE-ZZ202217)

Self-raised Scientific Research Fund of the Ministry of Health of Guangxi Province (Z20200923)

Self-raised Scientific Research Fund of the Ministry of Health of Guangxi Province (Z20191054)
License Information

Text and Data Mining valid from 2023-07-14

Version of Record valid from 2023-07-14
More Information

Article History

Received: 12 April 2023

Accepted: 28 June 2023

First Online: 14 July 2023

Declarations

:

: The authors have no conflicts of interest to declare that are relevant to the content of this article.

Document is current

Any future updates will be listed below